SCHEMBL8183130

SCHEMBL8183130

CN(C(=O)O)c1ccc2onc(NCCN3CCOCC3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 8/20 0.47
▸ CYP1A2 P05177 6/20 0.47
▸ HSD17B10 Q99714 4/20 0.47
▸ CLK4 Q9HAZ1 4/20 0.47
▸ USP2 O75604 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ LMNA P02545 8/20 0.46
▸ CYP2D6 P10635 5/20 0.46
▸ ALOX15 P16050 3/20 0.46
▸ CYP2C19 P33261 3/20 0.46
▸ HSP90AA1 P07900 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ HSP90AB1 P08238 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HBB P68871 1/20 0.46
▸ HIF1A Q16665 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CSNK2A1 P68400 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6953674 0.80 HSP90AA1 (0.55) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL3503323 0.77 HSP90AA1 (0.45) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL3504880 0.77 ALDH1A1 (0.56) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL8184622 0.76 CYP3A4 (0.45) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL3508765 0.75 ALDH1A1 (0.43) ALDH1A1LMNAALOX15TP53TSHR
SCHEMBL3504561 0.74 ALDH1A1 (0.46) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL3505036 0.74 ALDH1A1 (0.58) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL3510105 0.73 ALDH1A1 (0.50) HSD17B10USP2ALDH1A1LMNAALOX15
SCHEMBL3505581 0.73 HSP90AA1 (0.50) CYP3A4CYP1A2HSD17B10CLK4USP2
SCHEMBL9085767 0.72 NR1I3 (0.46) CYP3A4CYP1A2HSD17B10CLK4USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6046203-A USEFUL FOR THE TREATMENT OF VARIOUS MEMORY DYSFUNCTIONS CHARACTERIZED BY A DECREASED CHOLINERGIC FUNCTION SUCH AS ALZHEIMER'S DISEASE; ALSO INHIBIT MONOAMINE OXIDASE AND HENCE ARE USEFUL AS ANTIDEPRESSANTS AVENTIS PHARMACEUTICALS INC. (US) 2000-04-04 — — US disclosed
Send feedback